

2026 Annual GI DST Meeting

Breakfast 7:30 am

**Spencer Hotel & Conference Centre,
551 Windemere Road, London**

***Directions:** Please drive to the right of the mansion, drive down the hill and park on the south side of the building. Enter using "Reception" door. Event is on the 2nd floor.*

DRAFT AGENDA

Oak Meeting Room (Second Floor) - breakfast is located outside room

7:30 am Breakfast (assorted pastries, muffins, fresh cut fruit, yogurts, hard-boiled eggs, assorted hot/cold beverages)

Meeting Objectives: 1. Analyze emerging treatments for pancreatic cancer by comparing their mechanisms, efficacy, safety, and supporting evidence; 2. Analyze emerging chemoradiotherapy approaches for anal cancer and evaluate strategies for reducing treatment-related toxicity; 3. Compare local genetic-testing programs and peritoneal clinic services, including referral pathways, eligibility criteria, and available resources.

Oak Meeting Room (Second Floor)

8:30-8:35am Welcome
Belal Ahmad MD

8:35-9:15am Updates on anal cancer and toxicity reduction
Stephanie Gulstene MD
Objectives: 1- Review dose de-escalated chemoradiation for anal cancer, 2- Discuss treatment approaches for management of anal cancer in frail/elderly patients, 3 - Review current chemoradiation trials
9:10-9:15am Q & A Session

9:15-9:45am Review of New Multigene Panel testing for GI patients & how to "Mainstream"/Order Testing
Karen Panabaker MSc. MSc. CCGC. and Sameer Varmani MSc. CGC.
Objectives: 1 - To review the OH-PGP eligibility criteria for multigene panel testing for GI indications. 2 - To explain the new hereditary core panel and why it is recommended over the GI/polyposis panels. 3 - To explain what "mainstreaming" is and how to appropriately consent a patient and order gene panel testing.
9:35-9:40am – Q & A session

9:45-10:25am Update on Multidisciplinary Peritoneal Clinic at Verspeeten Family Cancer Centre

Elena Tsvetkova MD (on behalf of Allison Maciver MD)

Objectives:

10:05-10:10am Q & A Session

10:25-11:00am Break

2nd Floor Lobby

11:00-11:40am New drugs in GI cancer – what we all have to know

Mark Vincent MD

Objectives: 1. Analyze emerging therapeutic compounds for colorectal and pancreatic cancer, including their mechanisms of action and clinical evidence; 2. Analyze the clinical applications of new therapeutic compounds. 3. Analyze access considerations for new therapeutic compounds including cost, availability, eligibility, and health-equity implications.

11:10-11:15am Q & A Session

11:40-12:00am Latest in RT for Pancreatic Cancer

Tim Nguyen

12:00pm

Lunch - Asher's Dining Room (1st Floor)